![conference banner](/images/conference-banner.jpeg)
Abstract
Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Current Drug Targets
Title: Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Volume: 2 Issue: 3
Author(s): Gene C. Palmer
Affiliation:
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Abstract: Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Export Options
About this article
Cite this article as:
Palmer C. Gene, Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348335
DOI https://dx.doi.org/10.2174/1389450013348335 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the Neurological Thoughts?)
Current Molecular Medicine Aberrant Connection Formation and Glia Involvement in the Progression of Pharmacoresistant Mesial Temporal Lobe Epilepsy
Current Pharmaceutical Design Modeling Neuronal Diseases in Zebrafish in the Era of CRISPR
Current Neuropharmacology Imaging Markers of Neurologic Damage in COVID-19: A Systematic Review
Current Medicinal Chemistry Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review
Recent Patents on Biotechnology Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Phytochemical Analysis with Antioxidant and Cytotoxicity Studies of the Bioactive Principles from Zanthoxylum capense (Small Knobwood)
Anti-Cancer Agents in Medicinal Chemistry Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Bispidine as a Privileged Scaffold
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Metal Transport and Homeostasis within the Human Body: Toxicity Associated with Transport Abnormalities
Current Medicinal Chemistry Synthesis of 1H-1,2,3-triazoles and Study of their Antifungal and Cytotoxicity Activities
Medicinal Chemistry Physiology and Pathophysiology of Na+/H+ Exchange Isoform 1 in the Central Nervous System
Current Neurovascular Research Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design The Impact of Ancillary Subunits on Small-Molecule Interactions with Voltage-Gated Potassium Channels
Current Pharmaceutical Design Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research